Translocation activity of C-terminal domain of Pestivirus E<sup>ns</sup> and ribotoxin L3 loop.

J.P.M. Langedijk<sup>1,2.</sup>

<sup>1</sup>Department of Mammalian Virology, Institute for Animal Science and Health (ID-Lelystad), P.O. Box 65, 8200 AB, Lelystad, The Netherlands.

<sup>2</sup>Peptide systems B.V., Lelystad, The Netherlands.

*Address correspondence and reprint requests to J.P.M. Langedijk, Ph.D., Mailing address: Department of Mammalian Virology, Institute for Animal Science and Health (ID-Lelystad), Edelhertweg 15, P.O. Box 65, 8200 AB, Lelystad, The Netherlands.

Telephone :31-320-238271
Fax :31-320-238120
Email :j.p.m.langedijk@id.wag-ur.nl

Running title: transporter peptides.
Summary

The Pestivirus envelope glycoprotein Erns has RNase activity and therefore was suspected to enter cells to cleave RNA. The protein contains an RNase domain with a C-terminal extension, which shows homology with a membrane active peptide. The modular architecture and the C-terminal homology suggested that the C-terminus could be responsible for the presumed translocation. Peptides corresponding to the C-terminal domain of Erns and also the homologous L3-loop of ribotoxin II were indeed able to translocate across the eukaryotic cell membrane and were targeted to the nucleoli. The entire Erns protein was also able to translocate into the cell. Furthermore, other labeled proteins and even active enzymes could be transported inside the cell when they were attached to the C-terminal Erns peptide. Translocation was energy independent and not mediated by a protein receptor. The peptides showed no specificity for cell type or species.
Introduction

Classical swine fever virus (CSFV), bovine viral diarrhea virus (BVDV), and border disease virus (BDV) belong to the genus *Pestivirus* of the *Flaviviridae* family (1). CSFV is restricted to swine whereas BVDV and BDV have been isolated from several species such as cattle, swine, sheep, deer and giraffes (2). The disease is characterized by fever and hemorrhages and can run an acute or chronic course. Pestiviruses are plus-stranded RNA viruses whose genome comprises one long open reading frame (3-5). The structural proteins include a nucleocapsid protein C and three envelope glycoproteins E\textsubscript{ms}, E1 and E2 (6).

The envelope glycoprotein E\textsubscript{ms} is a disulfide linked homodimer of approximately 90 kD and approximately half of the molecular weight is contributed by carbohydrates (7,8). It is found on the surface of pestivirus infected cells and is secreted in the medium (8). E\textsubscript{ms} was able to bind many cell types (9) and binding of E\textsubscript{ms} is probably mediated by glycosaminoglycans (10,11). Two stretches of E\textsubscript{ms} show sequence homology with ribonuclease Rh, a new class of microbial ribonuclease of *Rhizopus niveus*, member of the T\textsubscript{2}S RNase superfamily (12). In line with this homology, E\textsubscript{ms} indeed contains RNase activity (13,14). E\textsubscript{ms} shows immunosuppressive activity since it induced apoptosis in ConA stimulated T-cells of several species (15). However, the function for its RNase activity remains elusive. Because an extracellular, secreted protein with RNase activity most likely has an intracellular target, it was anticipated that the molecule had some kind of way to enter the cell.

This study describes a modular architecture of the E\textsubscript{ms} protein and shows that the C-terminal domain was able to translocate across eukaryotic cell membranes. It was verified that also the full-length E\textsubscript{ms} was translocated into cells and the C-terminal E\textsubscript{ms} domain could be used as a general transport peptide to bring large enzymes in the cell. The basic E\textsubscript{ms} peptide seems to have a similar ability to translocate proteins as recently developed carrier peptides like HIV-1 Tat (48-60) and Antennapedia (43-58) (16-18).

Experimental Procedures

**Peptide synthesis.** Peptides were selected from the C-terminal region, (residues 191 – 227) of CSFV E\textsubscript{ms}, strain Alfort 187 (19) and the L3 loop of restrictocin (residues 59 – 88) (20) and magainin-1 (21). Also an unrelated control peptide was synthesized of a length comparable to the pestivirus E\textsubscript{ms} peptide.

CSFV: acetyl-ENARQGAARV TSWLGRQLRI AGKRLEGRSK TWFGAYA-COOH
Transporter peptides

CSFV : biotin-ENARQGAARV TSWLGRQLRI AGKRLEGRSK TWFGAYA-COOH
L3 : biotin-GNGKLIKGRTPIKFGKADCDRPPKHSQNGMGK-NH2
Mag-1 : biotin-GIGKFLHSAGKFGKAFVGEIMKS-NH2
Control: biotin-WWKGTLTFTAKMRSSNMWNPEQQHTTTAENIGKYIPNIGNG-NH2

Also panels of truncated CSFV Enr peptides and restrictocin L3 peptides were synthesized to elucidate the minimal membrane active region (Table 1,2).

Peptides were synthesized according to standard procedures on an Applied Biosystems 430A synthesizer or on a Hamilton Microlab 2200 (Reno, NV, USA) using Fmoc/HBTU chemistry. (22) After removal of the last Fmoc group, peptides were biotinylated using 0.45 M biotin which was activated for 15 minutes in 0.45 M HBTU/HOBt in DMF. After 1 h the reaction was stopped by washing five times with NMP and three times with EtOH. The purity of the peptides was >90% as determined by analytical LC/MS.

Recombinant protein. Enr of CSFV strain C, (amino acids 268 to 494 of the CSFV polyprotein) was expressed by a recombinant baculovirus in sf21 cells as described previously (10,14).

Translocation assay. Translocation of the peptide across the plasma membrane was studied by incubation of live cells in suspension or subconfluent monolayers on coverslips with biotinylated peptide (200 to 0.4 µg/ml culture medium) for 1, 10, 30, 45 or 120 minutes. After the time period, cells were fixed with 4% paraformaldehyde or cold methanol and labeled with streptavidin-FITC as described above. Fixed cells were inspected with fluorescence microscopy. Internalization was established with confocal microscopy. Comparison of translocation activity of different peptides was done by visual inspection of fluorescence intensity of titrated peptides that were stained by streptavidin-FITC. The following cell lines were used: A72, canine fibroblast tumor cells; MDCK, canine kidney epithelial cells; CCO, sheat-fish ovary cells; EK-1, Eel Kidney cells; CHS-E, salmon embryonal cells; BUEC, Bovine umbilical endothelial cells; BFDL, Bovine fetal diploid lung cells (fibroblast); PUEC, Porcine umbilical endothelial cells; HT 29, colorectal adenocarcinoma, colon epithelial cells; CaCo-2, colorectal adenocarcinoma, colon epithelial cells; HeLa, adenocarcinoma, cervix; Vero, normal monkey kidney epithelial cells; SK6, Swine Kidney cells; NPTTh, Newborn Pig Thyroid cells; ECTC, Embryonal Calf Thyroid cells; MDBK, normal bovine kidney epithelial
Transporter peptides
cells; EBTr, Epithelial Bovine Trachea cells; Bovine sperm cells; Sp20 mouse myeloma B-cells.

**Enzymatic staining.** Enzymatic activity of translocated streptavidin - Horseradish peroxidase (DAKO, Denmark) was assessed by staining with 0.02% AEC for 5 minutes and translocated streptavidin - β-Galactosidase (Sigma, St. Louis, MO) by staining with 0.1% X-Gal for 20 minutes.

**Confocal cell microscopy.** Stained cells as described above were analyzed using a confocal laser scanning microscope with an Argon laser, using an excitation wavelength of 488 nm and an emission of 515 nm using a BHS block.

**Hemolytic assay.** Hemolytic activity of various peptide concentrations were determined by incubation with human, guinee pig or sheep erythrocyte suspensions (final erythrocyte concentration, 1% v/v) for 1h at 37 °C. After cooling and centrifugation, the optical density of the supernatants were measured at 540 nm. Peptide concentrations causing 50% hemolysis (EC₅₀) were derived from the dose-response curves.

**Generation of Transmembrane Potential.** Erythrocytes were suspended in a buffer (10mM Hepes/150 mM (NaCl + KCl)/ 1 mM EDTA, pH 7.4) containing 97 mM (-9 mV) or 4 mM (-70 mV) K⁺. The resting potential of −9 mV approximates the resting potential of human erythrocytes (23). The transmembrane potential was generated by addition of valinomycin (6.7 μM for 1% hematocrit).

**Clonogenicity of mammalian cells.** HeLa or EBTr cells were cultured in DMEM, supplemented with 20 % foetal bovine serum and antibiotics in a humidified atmosphere supplied with 5% CO₂ at 37 C. Exponentially growing cells were treated with trypsin and transferred to wells of a 96-wells microtiter plate. Resulting in approximately 300 cells for each 30 μl of growth medium containing various concentrations of peptide. After incubation for 75 min (the plates were incubated upside down to avoid anchorage), the cells were transferred and plated in wells of tissue culture plates, which contained 100 μl of growth medium. Cell growth was checked after 3 to 6 days.
Transporter peptides

*Colocalization stains.* Nucleoli-specific staining was performed as described (24). In short, cells were incubated for 30 minutes with biotinylated peptide as described above. After washing, the cells were fixed with methanol at –20 °C, washed with sodium acetate buffer (0.01M; pH 4.9). Cells were washed and incubated with 40 µl streptavidin-TexasRed (10 µg/ml) at 37 °C. incubated with Acridine Orange (1 µg/ml; RT, pH 4.9), washed and incubated with 0.01% methylgreen (pH4.9). Cells were inspected with fluorescence microscopy at 490 nm, 595/615 nm and at 503/515 nm.
Transporter peptides

Results

*Sequence analysis.* A structural model of Erns was built by homology modeling based on an approximate sequence alignment of pestivirus Erns with ribonuclease Rh (RNase Rh) (Langedijk et al., manuscript in preparation). The alignment, which is shown schematically in Figure 1, showed that the 37 C-terminal residues of Erns do not align with RNase Rh and seem to form a separate region. The C-terminal region has no potential glycosylation sites, has a high number of positive charges and a high score for amphipathic helicity. A helical wheel representation of residues 194 – 220 shows an amphipathic helix with a hydrophobic face and a positively charged face (Figure 2). The only three residues that do not correspond with the amphipathicity are Ile210, Arg214 and Arg218. Such a positively charged domain in an RNase molecule is not unique for Erns but has also been observed in type II ribotoxins, another class of RNases. This class of RNases are extracellular cytotoxins that are able to translocate across phospholipid bilayers (25) and hydrolyze the large ribosomal RNA (26). Although ribotoxins are known to enter cells, it is not known which region of the protein is responsible for translocation. The type II ribotoxins like α-sarcin and restrictocin contain a large inserted L3 loop (residue 53 – 91) compared with other RNases of the T1 superfamily (27,28). This loop has structural similarity (but no sequence similarity) to loops found in lectin sugar-binding domains and may be responsible for the ribotoxins ability to bind the cell surface (27). The C-terminal domain of Erns has approximately the same length and contains similar sequence motifs as the ribotoxin II L3 loop (Figure 3). Although the sequence similarity between the ribotoxin L3 loop and the C-terminus of Erns is low (Figure 3), it is higher than the sequence similarity between L3 and the structurally similar lectin binding domains (27). Although the ribotoxin L3 loop is also positively charged, it has no apparent amphipathic character. Another interesting homology of the Erns C-terminal region is with the membrane interacting peptide magainin. The center of the Erns peptide has sequence homology with the N-terminal half of magainin (Figure 3). This homology is even higher compared to the homology of magainin with other pore forming peptides that have been described (29).

*Erns translocation.* To test whether the entire Erns dimer was able to translocate into epithelial cells, recombinant Erns of C-strain virus was incubated for 45 minutes with EBTr cells grown on coverslips overnight. After washing with PBS the cells were fixed with cold methanol and Erns was detected by incubation with a mix of monoclonal antibodies 140.1 and C5 (1/200) directed against Erns, and a second incubation with Rabbit anti Mouse - FITC (1/70) (F0261,
DAKO, Denmark). Erns could be detected outside as well as inside the cell by confocal microscopy. Accumulation could be observed around the nucleus (Figure 4).

**Peptide translocation.** Because the C-terminal region was identified as a separate domain that shows homology with a pore forming peptide and a peptide that probably interacts with cell surfaces, peptides were synthesized corresponding to the C-terminal domain and tested for translocation activity.

Cell suspensions (mouse myeloma and bovine sperm) and subconfluent monolayers of 17 different cell types (see Experimental procedures) were incubated for 1 h with biotinylated E<sup>ms</sup> peptide and fixed with cold methanol. Inspection with fluorescent microscopy and confocal microscopy showed that the peptide had penetrated inside all tested cell types. No obvious differences in cellular distribution or intensity were observed between cell types. Next, EBTr cells were incubated with biotinylated E<sup>ms</sup> peptide and fixed after different time intervals. The peptide entered the cell within 1 minute and optimal fluorescence was established after 30 minutes (Figure 5). After longer incubation times (3 h) the image was less clear. It is not known whether this is due to cellular changes or proteolysis of the peptide. The translocated peptide was distributed around the nucleus in membranous parts in the cytosol and, in contrast to the native protein, clear accumulation in the nucleoli was observed. The peptide has a similar intracellular localization as a known transport peptide like the Antennapedia (43-58) peptide.

Translocation was also observed at 4 °C and could not be competed by a 10 times excess of unbiotinylated E<sup>ms</sup> peptide (data not shown). Therefore, the mechanism is energy independent and not receptor mediated.

**Translocation of homologous peptides and mapping of translocation region.** The part of the E<sup>ms</sup> C-terminal region responsible for translocation was mapped precisely by testing the translocation activity of a panel of truncations of the E<sup>ms</sup> peptide and some peptides with N-terminal additions and deletions and C-terminal deletions (Table 1). Deletion of the seven most C-terminal residues and the three N-terminal residues increased the translocation activity of the peptide (Table 1). The most active biotinylated peptide (residues 194 - 220) still showed fluorescence above background at 250 nM with streptavidin-FITC. Because the E<sup>ms</sup> peptide showed some resemblance with the ribotoxin L3 loop and some sequence homology with magainin, these peptides were also tested for translocation activity (Figure 6). At 54 to 2 μM the biotinylated E<sup>ms</sup> peptide and the biotinylated L3 peptide show clear
translocation activity and the biotinylated magainin-1 peptide does not. The part of the restrictocin L3-loop responsible for translocation was mapped by testing the translocation activity of a panel of truncations of L3 loop peptides (Table 2). A short 13-residue peptide N-terminal to the cysteine displayed the highest translocation activity.

Transport of proteins. Next, it was tested whether the peptide could be used as a general transporter for cargoes other then Erns. This was tested by coupling labeled avidin and streptavidin to the biotinylated peptide. After mixing equimolar amounts of streptavidin-FITC (60 kD, nonglycosylated, neutral) or avidin-TexasRed (66 kD, glycosylated, pI = 10.5) with the most active E<sup>ms</sup> peptide (residues 194-220) (3 µM) it was possible to transport streptavidin-FITC and avidin-TexasRed inside the cell and the nucleus (Figure 7). Transport seems highly efficient because internalization of the peptide-streptavidin-FITC complex was still visible at a peptide concentration 20 times lower than the uncomplexed peptide (0.05 µM compared to 1 µM). Also in the case of streptavidin transport, the amount of accumulation was the same at 37°C and 4°C, which suggest that also the transport of larger cargoes is independent of endocytosis. The biotinylated restrictocin L3 peptide (residues 60 – 89) was not able to translocate 1 µM avidin-TexasRed or streptavidin-FITC (data not shown). Next, it was checked whether also large active enzymes could be translocated into the cell and tested for their enzymatic activity. This was tested by coupling streptavidin - Horseradish peroxidase (HRP) and streptavidin -β-galactosidase to the biotinylated peptide. A preformed complex of E<sup>ms</sup> peptide with streptavidin-HP (104 kD) and a preformed complex of E<sup>ms</sup> peptide with β-galactosidase (524 kD) was incubated with EBTr cells for 30 minutes. After washing, fixing with cold methanol and incubation with the respective substrates (Experimental procedures), the translocated active enzymes could be detected in the cytosol and the nucleoli (Figure 8).

Toxicity. Effective, non-toxic transport peptides should preferably have high translocation activity and low hemolytic activity and/or toxic activity. To check whether the membrane destabilizing activity had a general toxic effect on cells, hemolytic activity, tryphan blue exclusion and influence on cell growth was tested. EBTr cells were tested for tryphan blue leakage after peptide incubation for 30 minutes. Only at high concentrations of peptide (>35 µM) some tryphan blue could be determined inside the cell, especially in areas in the nucleus. Hemolysis of erythrocytes can also be indicative for lytic effect of the peptides on eukaryotic
cell membranes. Hemolysis of erythrocytes from several species was tested with the panel of Erns peptides (Table 1). The different peptides show a broad range of hemolytic activities on guineepig erythrocytes. The peptide with the highest translocation activity (residues 194 – 220) has a low hemolytic activity. No significant hemolysis was observed with sheep and human erythrocytes. The effect of the Erns peptide on cell growth of HeLa cells and EBTr cells was determined in a clonogenicity assay as shown in Table 3. These data correspond to the other toxicity assays and indicate that the translocation activity is much higher than the cytotoxic activity.

Membrane potential. Because the translocation seemed energy independent, it was tested whether the membrane potential could be the driving force for translocation. Because membrane activity measured with a hemolysis test correlated to some extent with translocation activity, the influence of membrane potential on hemolysis of human red blood cells was tested. Hemolysis is a straightforward test to study membrane activity and the membrane potential of erythrocytes can be easily manipulated by changing the sodium concentration in the medium. Hemolysis at membrane potentials of -9 mV and -70 mV shows that hemolysis was much higher at higher membrane potential (Figure 9).

Discussion

The Pestiviral surface protein Erns is unique because it is the only known viral surface protein with RNase activity (13,14). Although the biological function of the protein is not understood, it may be possible that, just as ribotoxins, the target for the protein is intracellular or intranuclear RNA. Therefore, we anticipated that the molecule had some kind of way to enter the cell. However, except for some specialized proteins like toxins, internalization of macromolecules can only be achieved through the classical endocytosis pathway. In this study, it was shown that the entire recombinant Erns dimer was indeed able to translocate into cells. Sequence analysis indicated that the first 190 residues of Erns show homology to RNases of the T2/S superfamily and that the C-terminal 37 residues probably fold as a separate domain (Langedijk et al., in preparation). This C-terminal domain is non-glycosylated, highly positively charged, amphipathic and shows a slight homology with the
pore-forming, antibacterial peptide magainin, and with a large loop in type II ribotoxins, which was expected to bind cell surfaces (27). Therefore, the C-terminal domain of Erns was most likely responsible for the translocation activity. It was demonstrated that indeed, a peptide of 37 residues corresponding to the C-terminal domain of Erns translocates very efficiently over the plasma membrane of all tested cell types of a wide variety of species. The peptide is targeted to the nucleoli and to cytoplasmic membranes and localizes in the same areas as other known transport peptides like the HIV-1 Tat and Antennapedia peptide (data not shown).

The translocation is very fast (< 1 minute), it is energy independent and receptor independent. The independence of binding to a saturable receptor agrees with the lack of cell specificity and suggests that the peptide interacts directly with fosfolipids, as has been described for another transport peptide (30). Because the hemolytic activity correlated to some extent with translocation activity, the influence was tested of membrane potential on hemolysis of human red blood cells. Figure 9 shows that the membrane activity was dependent on the membrane potential. Since the translocation is energy independent, the membrane potential may therefore be the driving force for translocation.

Because the elucidation of the translocating Erns peptide was inspired by the homology with magainin and the ribotoxin L3 loop, it was also tested whether a peptide corresponding to the L3 loop had translocating activity. Although previously another, more hydrophobic region of alpha-sarcin was shown to interact with membranes (31), in this study it was shown that a more N-terminally located peptide corresponding to the restrictocin L3 loop had translocation activity (Figure 6). Perhaps both regions contribute to membrane translocation in the native protein.

To elucidate the exact region of the peptides responsible for translocation, panels of Erns peptides and restrictocin peptides with different lengths were synthesized. The most active translocating Erns peptide was 10 residues shorter (residue 194-220) then the full-length C-terminal peptide of Erns (191-227) and it was less toxic (Table 1). The most active translocating restrictocin L3 peptide was 13 residues long, which corresponds to the N-terminal half of the L3 loop, before the cystine bridge which divides the loop in two parts in the native protein. Just like other known transporter peptides, the mapping showed that basic residues were important for translocation activity.

The homology between the most active restrictocin L3 and the Erns peptide is only two small sequence motifs (GR and GK) which is much lower compared with the homology between Erns peptide and magainin, which has no translocation activity (Figure 6). Magainin forms a
Transporter peptides

perfect amphipathic helix, thus amphipathicity is not important for transport peptides. In contrast to the E\textsuperscript{ms} peptide, the L3 loop peptide has no amphipathicity when represented as a helix. Furthermore, the L3 loop contains a helix-breaking proline. It has been suggested that there may be several different translocation mechanisms for the different peptides and that they not necessarily have to form a helix (32). Recently, several transport peptides have been discovered which all have a very different origin and no obvious sequence homology can be observed (16,18,32-34). The only resemblance is the high amount of positive charges.

The mapping experiments also proved that the peptide did not only translocate itself and a biotin molecule, but also peptide cargoes could be transported. Next, it was shown that the peptide could be used as a general transporter for proteins different from E\textsuperscript{ms}. Streptavidin and avidin, which have different physical characteristics, could be transported into cells when complexed to the E\textsuperscript{ms} peptide. The labeled proteins were targeted to the same intracellular regions as the peptide and are concentrated in vesicle-like structures around the nucleus and spread through the cytoplasm. In contrast to recombinant E\textsuperscript{ms}, nucleoli targeting was observed, although it was less pronounced than the peptide (Figure 7). Even the enzymes HRP and β-Gal conjugated to streptavidin could be efficiently transported into cells when complexed with the E\textsuperscript{ms} peptide. Internalized enzymes retained their activity and clear substrate conversion was observed in the nucleoli. Especially the streptavidin-β-Gal conjugate which has a Mw as high as 524 kD and a pI as low as 4.6 illustrates the remarkable efficacy of the transport peptide. In contrast, the restrictocin L3 peptide was not able to translocate the selected protein cargoes. Perhaps the difference in transport ability of the two peptides is based on the pI which is lower for the L3 peptide (pI = 10.7) compared with the E\textsuperscript{ms} peptide (pI = 12.7). Accordingly, the transport ability of the peptides may be increased increasing the pI of the peptides. Another difference between both peptides is that L3 is an internal peptide and the E\textsuperscript{ms} peptide is originally a terminal peptide and for that reason may be more efficient in the described experiments in which it was terminally attached.

The demonstration of a translocation domain within E\textsuperscript{ms} adds a novel facet to this so far poorly understood pestiviral glycoprotein and may encourage studies on how a secreted RNase is involved in the survival strategy of an RNA virus. The function of E\textsuperscript{ms} and the function of its RNase activity remains elusive but the translocation suggests that it may control protein synthesis and transcription in infected cells as well as non-infected cells. The E\textsuperscript{ms} peptide and the ribotoxin L3 peptide may be used as a delivery tool to transport a diverse set of potential therapeutics inside the cell.
Acknowledgements

I would like to thank Rob Buijs, Mark de Groot and Wim Schaaper for technical assistance.
Transporter peptides

References


Transporter peptides


Transporter peptides

Descriptions of the figures

Figure 1.
Schematic representation of alignment of pestivirus E\textsuperscript{ms} with RNase Rh which indicates the modular organization of E\textsuperscript{ms}. E\textsuperscript{ms} consists of an RNase domain (dotted) and a C-terminal membrane active domain (filled black). Strongly homologous RNase active site domains are shown as checkered boxes. Potential glycosylation sites are shown as ellipses.

Figure 2.
Helical wheel representation of residues 194 – 220 of CSFV E\textsuperscript{ms}. Hydrophobic residues (filled black) and positive residues (dotted) are indicated.

Figure 3.
Sequence alignment of pestivirus E\textsuperscript{ms} C-terminal domains with magainin-1 and the L3 loop of restrictocin(21,28). Residues within one distance unit from CSFV are boxed. Gaps are indicated by dashes.

Figure 4.
Distribution of purified recombinant CSFV E\textsuperscript{ms}, strain C (a) or supernatant of mock infected sf21 cells (b). EBTr cells were incubated with 1 \textmu M E\textsuperscript{ms} for 45 minutes. Fixed cells were incubated with a mix of monoclonals directed against E\textsuperscript{ms}, and subsequently incubated with Rabbit anti Mouse - FITC. Fluorescent micrographs using confocal microscopy (600 X).

Figure 5.
Distribution of biotinylated CSFV E\textsuperscript{ms} peptide (a,c) and biotinylated control peptide (b) (25 \textmu M) after 30 minutes of incubation with subconfluent EBTr cells grown on a 10-well microscope slide. Cells were fixed with cold methanol and biotinylated peptide was visualized by staining with avidin-FITC for 30 minutes. Fluorescent micrograph (250 X)(a,b) or fluorescent micrograph using confocal microscope (600 X) (c).

Figure 6.
Distribution of biotinylated L3 peptide (a) and magainin-1 peptide (b) (6 \textmu M) after 30 minutes of incubation with subconfluent EBTr cells grown on a 10-well microscope slide.
Transporter peptides

Cells were fixed with cold methanol and biotinylated peptide was visualized by staining with avidin-FITC for 30 minutes. Fluorescent micrograph (250 X).

Figure 7.

Transport of avidin and streptavidin.
EBTr cells were incubated for 30 minutes with a complex of biotinylated E\textsuperscript{ms} peptide and Avidin-TexasRed (a) or streptavidin-FITC (c) (3 µM). As a control, EBTr cells were incubated with a mixture of unbiotinylated peptide and avidin-TexasRed (b) or streptavidin-FITC (d) (3 µM). Peptide corresponds to residues 194-220 of E\textsuperscript{ms}.

Figure 8.
Transport of streptavidin-HRP and streptavidin-β-Gal. EBTr cells were incubated for 30 minutes with a preformed complex of E\textsuperscript{ms} peptide with streptavidin-HRP, 0.5 µM (a); preformed complex of E\textsuperscript{ms} peptide with streptavidin-β-Gal. 2 µM (b); control streptavidin-HRP 0.5 µM (c); control streptavidin-β-Gal. 2 µM (d). Staining was performed as described in Experimental procedures.

Figure 9.
Influence of membrane potential on hemolysis of human erythrocytes. Erythrocytes were suspended in a buffer (10 mM Hepes/150 mM (NaCl + KCl)/ 1 mM EDTA, pH 7.4) containing 97 mM (-9 mV) or 4 mM (-70 mV) K\textsuperscript{+}. The transmembrane potential was generated by addition of valinomycin.
Table 1. Determination of minimal translocating sequence of E<sup>ns</sup>.

<table>
<thead>
<tr>
<th>Residue number</th>
<th>Sequence'</th>
<th>Internalized fluorescence</th>
<th>Hemolysis (mg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>191-227</td>
<td>$\text{ENARQGAARVTSWLGRQLRIAGKRLEGRSKTWFGAYA#}$</td>
<td>++++</td>
<td>0.07</td>
</tr>
<tr>
<td>184-223</td>
<td>$\text{GDTMTENARQGAARVTSWLGRQLRIAGKRLEGRSKTWF#}$</td>
<td>++++</td>
<td>0.15</td>
</tr>
<tr>
<td>181-220</td>
<td>$\text{YLLDGMTNTENARQGAARVTSWLGRQLRIAGKRLEGRSK#}$</td>
<td>++++</td>
<td>0.09</td>
</tr>
<tr>
<td>177-216</td>
<td>$\text{DTALYLLDGMTNTENARQGAARVTSWLGRQLRIAGKRLE#}$</td>
<td>++</td>
<td>0.23</td>
</tr>
<tr>
<td>172-211</td>
<td>$\text{GSLLQDTALYLLDGMTNTENARQGAARVTSWLGRQLRIA#}$</td>
<td>+</td>
<td>&gt;0.33</td>
</tr>
<tr>
<td>191-223</td>
<td>$\text{ENARQGAARVTSWLGRQLRIAGKRLEGRSKTWF#}$</td>
<td>++++</td>
<td>0.15</td>
</tr>
<tr>
<td>191-220</td>
<td>$\text{ENARQGAARVTSWLGRQLRIAGKRLEGRSK#}$</td>
<td>++++</td>
<td>0.31</td>
</tr>
<tr>
<td>191-216</td>
<td>$\text{ENARQGAARVTSWLGRQLRIAGKRLE#}$</td>
<td>++</td>
<td>&gt;0.33</td>
</tr>
<tr>
<td>191-211</td>
<td>$\text{ENARQGAARVTSWLGRQLRIA#}$</td>
<td>+</td>
<td>&gt;0.33</td>
</tr>
<tr>
<td>194-220</td>
<td>$\text{RQGAARVTSWLGRQLRIAGKRLEGRSK#}$</td>
<td>++++</td>
<td>0.26</td>
</tr>
<tr>
<td>194-218</td>
<td>$\text{RQGAARVTSWLGRQLRIAGKRLEGR#}$</td>
<td>++++</td>
<td>N.D.</td>
</tr>
<tr>
<td>196-220</td>
<td>$\text{GRQGAARVTSWLGRQLRIAGKRLEGRSK#}$</td>
<td>+++</td>
<td>0.16</td>
</tr>
<tr>
<td>199-220</td>
<td>$\text{RQGAARVTSWLGRQLRIAGKRLEGRSK#}$</td>
<td>++</td>
<td>0.18</td>
</tr>
<tr>
<td>202-220</td>
<td>$\text{GRQGAARVTSWLGRQLRIAGKRLEGRSK#}$</td>
<td>+</td>
<td>&gt;0.33</td>
</tr>
<tr>
<td>205-220</td>
<td>$\text{GRQRIAGKRLEGRSK#}$</td>
<td>+</td>
<td>&gt;0.33</td>
</tr>
</tbody>
</table>

1 $ = \text{biotin, # = amide.}$

2 Sequence of peptide which showed highest translocation activity.

N.D. = not determined
### Table 2: Determination of minimal translocating sequence of restrictocin L3

<table>
<thead>
<tr>
<th>Residue number</th>
<th>Sequence</th>
<th>Internalized fluorescence</th>
</tr>
</thead>
<tbody>
<tr>
<td>57-89</td>
<td>$\text{GNGKLIKGRTPIKFGKACDRPPKHSQNGMGK}#$</td>
<td>++</td>
</tr>
<tr>
<td>57-87</td>
<td>$\text{GNGKLIKGRTPIKFGKACDRPPKHSQNGMGK}#$</td>
<td>+</td>
</tr>
<tr>
<td>60-89</td>
<td>$\text{KLIKGRTPIKFGKACDRPPKHSQNGMGK}#$</td>
<td>+++</td>
</tr>
<tr>
<td>63-89</td>
<td>$\text{KGRTPIKFGKACDRPPKHSQNGMGK}#$</td>
<td>+++</td>
</tr>
<tr>
<td>60-73</td>
<td>$\text{KLIKGRTPIKFGK}#$</td>
<td>+++</td>
</tr>
</tbody>
</table>

1 $ = $ biotin, # = amide.
Table 3. Peptide concentration that inhibits cell growth

<table>
<thead>
<tr>
<th>Cell type</th>
<th>E&lt;sup&gt;ms&lt;/sup&gt; peptide (191 – 227) (µM)</th>
<th>E&lt;sup&gt;ms&lt;/sup&gt; peptide (194 – 220) (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HeLa</td>
<td>50</td>
<td>40</td>
</tr>
<tr>
<td>EBTr</td>
<td>50</td>
<td>60</td>
</tr>
</tbody>
</table>
Transporter peptides

Figures

Figure 1

RNase Rh

Ems

ENAQRGAARVTSLGRQLRAGKRLEGRSKTWFGAYA
Transporter peptides

figure 2
Transporter peptides

Figure 3

<table>
<thead>
<tr>
<th>transporter peptide</th>
<th>sequence</th>
<th>notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>CSFV</td>
<td>ENARQGAARVTSLGRQLKLAGKRLEGR-SKTWFGAYA</td>
<td></td>
</tr>
<tr>
<td>CSFVb</td>
<td>EGARQGAARVTSLGRQLSTAGKRLEGR-SKTWFGAYA</td>
<td></td>
</tr>
<tr>
<td>BVDV</td>
<td>ESARQGTAKLTTWLGRQ1LRKLGKKLENK-SKTWFGAYA</td>
<td></td>
</tr>
<tr>
<td>bvdv-2</td>
<td>ESARQGTAKLTTWLGRQ1LRKLGKKLENK-SKTWFGAYA</td>
<td></td>
</tr>
<tr>
<td>BDV</td>
<td>ESARQGAATLTSWLGKQ1LRKLGKKLENK-SKTWFGAYA</td>
<td></td>
</tr>
<tr>
<td>Magainin</td>
<td>GIGKFLHSAGKFGIKFGRKADCPRPHSQMN</td>
<td></td>
</tr>
<tr>
<td>Restrictocin</td>
<td>--------DGNGKLIKGRTIKFKGKADCDRP</td>
<td></td>
</tr>
</tbody>
</table>
Transporter peptides

figure 4

a

b
Transporter peptides

Figure 5.
Transporter peptides

Figure 6

a

b
Transporter peptides

figure 7
Transporter peptides

Figure 8

a

b
d

27
Transporter peptides

figure 9

![Graph showing O.D.540 and hemolysis percentage against peptide concentration.]

-9 mV
-70 mV
Translocation activity of C-terminal domain of Pestivirus Erns and ribotoxin L3 loop
Johannes P. M. Langedijk

J. Biol. Chem. published online October 22, 2001

Access the most updated version of this article at doi: 10.1074/jbc.M104147200

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 0 references, 0 of which can be accessed free at
http://www.jbc.org/content/early/2001/10/22/jbc.M104147200.citation.full.html#ref-list-1